FES Cycling With BFR in the Spinal Cord Injury Population

Recruiting Phase 1 Interventional Study
Spinal Cord Injury Cardio Vascular Disease Metabolic Diseases, Type 2 Diabetes, Cardiovascular Disease
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 75
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Other
Participants needed
6 (estimated)
Sponsor
Dr. B. Catharine. Craven · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Cardiometabolic Disease (CMD) is the silent killer within the spinal cord injury/disease (SCI/D) population. Many SCI/D patients' initial CMD presentation is with a heart attack, stroke, or sudden cardiac death, highlighting the need for interventions to reduce CMD risk. CMD contributes to 46% of deaths, with 30-50% of the SCI/D population living with undiagnosed CMD. Treating CMD risk is more cha…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Adult (≥ 18 to ≤ 75yrs) * Male or female * Chronic Injury (\>1yr) * Diagnosis of SCI at levels between C5 to T10 (AIS A-D) with traumatic or non-traumatic etiology. * ≥3 Cardiometabolic risk parameters Exclusion Criteria: * A prior or current history of venous thromboembolis…
Contacts

Thomas P Walden, Ph.D

4165973422

thomas.walden@uhn.ca

CONTACT

Katherine Chan, MSc

4165973422

Katherine.chan@uhn.ca

CONTACT